Bank of Montreal Can Has $164.28 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Bank of Montreal Can grew its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 419,458 shares of the pharmaceutical company’s stock after buying an additional 56,423 shares during the quarter. Bank of Montreal Can owned 0.17% of Vertex Pharmaceuticals worth $164,277,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC increased its holdings in Vertex Pharmaceuticals by 15.0% during the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after purchasing an additional 579 shares in the last quarter. AE Wealth Management LLC boosted its position in shares of Vertex Pharmaceuticals by 112.0% during the second quarter. AE Wealth Management LLC now owns 2,468 shares of the pharmaceutical company’s stock valued at $1,099,000 after buying an additional 1,304 shares during the last quarter. Midwest Trust Co bought a new stake in Vertex Pharmaceuticals during the second quarter worth $254,000. PFG Advisors purchased a new stake in Vertex Pharmaceuticals in the 2nd quarter valued at $207,000. Finally, Allworth Financial LP raised its position in Vertex Pharmaceuticals by 77.9% in the 2nd quarter. Allworth Financial LP now owns 3,462 shares of the pharmaceutical company’s stock valued at $1,541,000 after buying an additional 1,516 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP Mark E. Bunnage sold 2,021 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, February 11th. The shares were sold at an average price of $460.43, for a total value of $930,529.03. Following the sale, the executive vice president owned 12,914 shares of the company’s stock, valued at approximately $5,945,993.02. The trade was a 13.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Charles F. Wagner, Jr. sold 9,532 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $461.00, for a total value of $4,394,252.00. Following the completion of the transaction, the executive vice president owned 37,725 shares in the company, valued at approximately $17,391,225. The trade was a 20.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 91,156 shares of company stock valued at $42,845,497. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $499.17 on Wednesday. The stock has a market capitalization of $126.80 billion, a price-to-earnings ratio of 32.56 and a beta of 0.31. Vertex Pharmaceuticals Incorporated has a one year low of $362.50 and a one year high of $519.68. The business’s fifty day moving average is $468.41 and its 200-day moving average is $436.53.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share for the quarter, missing the consensus estimate of $5.05 by ($0.02). Vertex Pharmaceuticals had a net margin of 32.94% and a return on equity of 24.30%. The company had revenue of $3.19 billion for the quarter, compared to the consensus estimate of $3.18 billion. During the same quarter in the previous year, the company posted $3.98 EPS. Vertex Pharmaceuticals’s quarterly revenue was up 9.5% compared to the same quarter last year. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Vertex Pharmaceuticals News Summary

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported positive Week‑36 interim results from the Phase 3 RAINIER trial for povetacicept — the study met its primary and all secondary endpoints, supporting the drug’s potential as a best‑in‑class treatment for IgA nephropathy. Vertex Announces Positive Week 36 Interim Analysis Results
• Positive Sentiment: News outlets note the trial win as a major validation — coverage emphasizes the result as a “key test” passed and calls the data “remarkable,” boosting confidence in Vertex’s kidney‑disease strategy. Vertex passes key test In quest to treat kidney diseases
• Positive Sentiment: Interim efficacy metrics cited in coverage (e.g., ~52% reduction in proteinuria) raise hopes for meaningful clinical benefit and potential for an accelerated FDA filing pathway, increasing the drug’s peak‑sales and valuation assumptions. VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
• Positive Sentiment: Multiple brokerages responded quickly with higher price targets and fresh buy/outperform ratings (examples: Morgan Stanley, BofA, Oppenheimer, HC Wainwright, Citi, Jefferies, BMO and others), reflecting analysts modeling substantial upside from povetacicept. Benzinga — analyst price target coverage
• Neutral Sentiment: Vertex presented at the Leerink Global Healthcare Conference (transcript available), which may provide additional detail on timing, filing plans and commercial strategy but is less market‑moving than the trial headlines. Vertex Presents at Leerink Global Healthcare Conference 2026 Transcript
• Neutral Sentiment: Market commentary and aggregator pieces (Barron’s, Yahoo, Investopedia, TipRanks) are amplifying the newsflow — helpful for liquidity and momentum but reflecting the same core trial announcement rather than new independent data. Investopedia — trial results coverage

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Oppenheimer lifted their price objective on shares of Vertex Pharmaceuticals from $540.00 to $600.00 and gave the stock an “outperform” rating in a report on Tuesday. HC Wainwright increased their target price on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the company a “buy” rating in a report on Tuesday. Scotiabank raised their price target on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a research report on Friday, February 13th. Royal Bank Of Canada cut their price target on shares of Vertex Pharmaceuticals from $546.00 to $541.00 and set an “outperform” rating on the stock in a report on Friday, February 13th. Finally, Bank of America upped their price objective on shares of Vertex Pharmaceuticals from $571.00 to $598.00 and gave the stock a “buy” rating in a research report on Tuesday. Twenty-three investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $551.77.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.